liphekolo tse ncha tse seng nyane tsa mofetše oa matšoafo

Kankere e seng e nyane ea lisele tsa matšoafo (NSCLC) ke sesosa se ka sehloohong sa mafu a amanang le mofets'e lefatšeng ka bophara. Ka lehlohonolo, tsoelo-pele e kholo ea mekhoa ea phekolo e ntse e hlaha, e fana ka tšepo e ncha bakeng sa liphello tse ntlafetseng le boleng ba bophelo. Sengoliloeng sena se hlahloba tsa morao-rao liphekolo tse ncha tse seng nyane tsa mofetše oa matšoafo, ho kenyeletsoa liphekolo tse lebisitsoeng, immunotherapies, metsoako ea chemotherapy, le liteko tse ncha tsa kliniki.Kutloisisa Kankere e Seng e Nyenyane ea Matšoafo ea Matšoafo (NSCLC)Kankere e seng e nyane ea lisele tsa matšoafo (NSCLC) ke mofuta o atileng haholo oa mofetše oa matšoafo, o nkang hoo e ka bang 80-85% ea litlhahlobo tsohle tsa mofetše oa matšoafo. E na le mefuta e mengata e fapaneng, ho kenyelletsa adenocarcinoma, squamous cell carcinoma, le carcinoma e kholo ea lisele. Boemo ba NSCLC nakong ea tlhahlobo bo ama haholo likhetho tsa kalafo le boits'oaro. Mehato ea pele ea NSCLC e ka 'na ea phekoloa ka ho buuoa, ha mehato e tsoetseng pele e atisa ho hloka phekolo e kopanetsoeng. Hangata liphekolo tsena li sebetsa hantle ebile li na le litla-morao tse fokolang ho feta chemotherapy ea setso. Lipheo tse tloaelehileng ho NSCLC li kenyelletsa EGFR, ALK, ROS1, BRAF, le MET.EGFR InhibitorsEpidermal growth factor receptor (EGFR) ke protheine e thusang lisele ho hōla le ho arohana. Lihlahala tse ling tsa NSCLC li na le liphetoho tsa liphatsa tsa lefutso tsa EGFR, tse lebisang kholong e sa laoleheng ea lisele. Li-inhibitors tsa EGFR, tse kang gefitinib, erlotinib, afatinib, le osimertinib, li thibela mosebetsi oa EGFR, ho liehisa kapa ho emisa ho hōla ha hlahala.Melemo: Hangata e sebetsa ho bakuli ba nang le liphetoho tsa EGFR, tse lebisang ho ntlafetseng ho phela le boleng ba bophelo.Litlamorao: Lekhopho la letlalo, letšollo, mokhathala.Osimertinib hangata ke phekolo e khethiloeng ea pele bakeng sa EGFR-mutated NSCLC, e bontšang katleho e phahameng ha e bapisoa le li-inhibitors tsa EGFR tsa pele ho nako. U ka ithuta ho eketsehileng ka EGFR inhibitors ho tswa ho Webosaete ea American Cancer Society.ALK InhibitorsAnaplastic lymphoma kinase (ALK) ke protheine e 'ngoe e ka fetoloang ho NSCLC. ALK inhibitors, tse kang crizotinib, ceritinib, alectinib, brigatinib, le lorlatinib, li lebisa protheine ea ALK, e thibela mosebetsi oa eona le ho thibela ho hōla ha hlahala.Melemo: E sebetsa hantle ho bakuli ba nang le li-rearrangements tsa ALK, tse hlahisang bophelo bo ntlafetseng le ho fokotsa tsoelo-pele ea mafu.Litlamorao: Liphetoho tsa pono, ho nyekeloa ke pelo, ho hlatsa, letšollo, mokhathala.Alectinib le Lorlatinib hangata ba khethoa kalafo ea pele ka lebaka la katleho ea bona e ntlafetseng le bokhoni ba ho phunyeletsa le mokoallo oa mali-boko, e leng ntho ea bohlokoa ho bakuli ba nang le metastase ea boko. Patlisiso ea Kankere UK e fana ka boitsebiso bo eketsehileng.ROS1 InhibitorsROS1 ke receptor tyrosine kinase eo, ha e kopantsoe le lefutso le leng, e ka tsamaisang kholo ea kankere. ROS1 inhibitors, joalo ka crizotinib le entrectinib, li sebelisoa ho phekola NSCLC ka li-fusion tsa ROS1.Melemo: Ho fokotseha ho hoholo ha hlahala le ho phela nako e telele ho bakuli ba nang le ROS1-positive NSCLC.Litlamorao: E ts'oanang le ALK inhibitors.Entrectinib e bontšitse tšepiso ka lebaka la bokhoni ba eona ba ho tšela mokoallo oa mali-boko, ho etsa hore e atlehe ho phekola metastase ea boko. Hlahloba Webosaete ea European Medicines Agency bakeng sa lintlha tse qaqileng.Immunotherapy bakeng sa NSCLCImmunotherapy e sebelisa matla a sesole sa 'mele ho loantša mofetše. Li-immune checkpoint inhibitors ke mofuta oa immunotherapy o thibelang liprotheine tse thibelang sesole sa 'mele ho hlasela lisele tsa mofetše.PD-1/PD-L1 InhibitorsProgrammed cell death protein 1 (PD-1) le programmed death-ligand 1 (PD-L1) ke liprotheine tse thusang lisele tsa mofetše ho qoba sesole sa 'mele. PD-1/PD-L1 inhibitors, tse kang pembrolizumab, nivolumab, atezolizumab, le durvalumab, li thibela liprotheine tsena, ho lumella sesole sa 'mele ho lemoha le ho hlasela lisele tsa mofetše.Melemo: Likarabo tse tšoarellang le ho pholoha ho ntlafetseng karolong e nyenyane ea bakuli ba NSCLC.Litlamorao: Litla-morao tse amanang le 'mele, tse kang pneumonitis, colitis, le hepatitis.Pembrolizumab e atisa ho sebelisoa e le phekolo ea pele bakeng sa bakuli ba NSCLC ba nang le polelo e phahameng ea PD-L1. Boitsebiso bo eketsehileng bo ka fumanoa ho Webosaete ea FDA.CTLA-4 InhibitorsCytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ke protheine e 'ngoe e ka hatellang sesole sa' mele. Ipilimumab ke CTLA-4 inhibitor e ka sebelisoang hammoho le PD-1 inhibitors ho matlafatsa karabelo ea 'mele ea ho itšireletsa mafung khahlanong le lisele tsa mofetše.Melemo: E ka ntlafatsa bophelo ha e kopantsoe le PD-1 inhibitors.Litlamorao: Litla-morao tsa bohlokoa tse amanang le 'mele oa ho itšireletsa mafung ha li bapisoa le li-inhibitors tsa PD-1 feela.Metsoako ea ChemotherapyLe hoja liphekolo tse lebisitsoeng le immunotherapies li fetotse phekolo ea NSCLC, chemotherapy e ntse e le khetho ea bohlokoa, haholo-holo ha e kopantsoe le mekhoa e meng ea phekolo. Kalafo e ncha e seng e nyane ea mofetše oa matšoafo oa lisele hangata e kenyelletsa ho kopanya chemotherapy le immunotherapy kapa liphekolo tse lebisitsoeng ho ntlafatsa katleho ea tsona.ChemoimmunotherapyHo kopanya chemotherapy le immunotherapy ho bontšitse litholoana tse tšepisang liphekolo tse ncha tse seng nyane tsa mofetše oa matšoafo. Mokhoa ona o phahamisa bokhoni ba chemotherapy ho senya lisele tsa mofetše le ho lokolla li-antigen, e leng se etsang hore li hlaseloe habonolo ke 'mele oa ho itšireletsa mafung. Keketso ea immunotherapy e ka eketsa karabelo ea 'mele ea ho itšireletsa mafung, e lebisang ho liphetho tse ntlafalitsoeng.Melemo: Lipalo tse ntlafetseng tsa ho pholoha le ho arabela ha li bapisoa le chemotherapy feela.Litlamorao: Kotsi e eketsehileng ea phekolo ea lik'hemik'hale le litla-morao tse amanang le 'mele oa ho itšireletsa mafung.Targeted Therapy and Chemotherapy CombinationsMaemong a mang, ho kopanya phekolo e lebisitsoeng le chemotherapy ho ka ba molemo, haholo-holo ho bakuli ba qalileng ho hanyetsa phekolo e lebisitsoeng feela. Mokhoa ona o ka thusa ho hlola mekhoa ea ho hanyetsa le ho ntlafatsa liphello tsa phekolo.Melemo: E ka khutlisetsa kutlo ho kalafo e lebisitsoeng le ho ntlafatsa bophelo.Litlamorao: Kotsi e eketsehileng ea litla-morao ho tsoa liphekolong tseo ka bobeli.Liteko tsa Kliniki: Bokamoso ba Kalafo ea NSCLC Liteko tsa bongaka ke lithuto tsa lipatlisiso tse hlahlobang. liphekolo tse ncha tse seng nyane tsa mofetše oa matšoafo le maano. Ho nka karolo tekong ea bongaka ho ka fana ka phihlello ea liphekolo tsa maemo a holimo tse e-so fumanehe ka bongata. Setsi sa Lipatlisiso sa Kankere sa Shandong Baofa se ikemiseditse ho ntshetsapele dipatlisiso tsa mofetshe mme se fana ka ditshebeletso le ho nka karolo ditekong tsa bongaka tse fanang ka phihlello ya dikalafo tsa moraorao tse eso fumanehe ka bongata. Ithute haholoanyane ka liteko tsa bongaka ho Shandong Baofa Cancer Research Institute.Liphekolo Tse Hlahang ho Liteko tsa Clinical Tšepisang tse ngata liphekolo tse ncha tse seng nyane tsa mofetše oa matšoafo hajoale li ntse li hlahlojoa litekong tsa bongaka, ho kenyelletsa:Li-antibody-drug conjugates (ADCs): Lithethefatsi tsena li fana ka chemotherapy ka kotloloho liseleng tsa mofetše, ho fokotsa tšenyo ea lisele tse phetseng hantle.Li-antibodies tse ikhethang: Li-antibodies tsena li tlama liseleng tsa mofetše le lisele tsa 'mele, li li kopanya ho matlafatsa karabelo ea 'mele ea ho itšireletsa mafung.Liphekolo tsa mehala (mohlala, CAR-T cell therapy): Liphekolo tsena li kenyelletsa ho fetola lisele tsa 'mele tsa ho itšireletsa mafung ho lebisa le ho senya lisele tsa mofetše.Ho phela le NSCLC: Lisebelisoa le TšehetsoHo phela le NSCLC ho ka ba phephetso, empa lisebelisoa tse ngata le lihlopha tsa tšehetso li fumaneha ho thusa bakuli le malapa a bona ho sebetsana ka katleho le lefu lena. Nahana ka ho hlahloba lisebelisoa ho tsoa mekhatlong e kang ea Mokhatlo oa Amerika oa Lung kapa ea LUNGevity Foundation.Boitlhotlhollo: Sengoliloeng sena ke sa merero ea tlhahisoleseling feela mme ha sea lokela ho nkuoa e le keletso ea bongaka. Ka kopo, buisana le mofani oa tlhokomelo ea bophelo bakeng sa likhothaletso tse ikhethileng tsa kalafo.